ProCE Banner Activity

An Expert’s Guide to Key Studies at the 2022 ASCO Genitourinary Cancers Symposium

Conference Coverage
Clinical Thought
Experts highlight key studies in bladder, prostate, and kidney cancers being presented at the upcoming 2022 Genitourinary Cancers Symposium annual meeting.

Released: February 15, 2022

Expiration: February 14, 2023

No longer available for credit.

Share

Faculty

Toni K. Choueiri

Toni K. Choueiri, MD

Director, Lank Center for Genitourinary Oncology
Medical Director, International Strategic Initiatives
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts 

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

Seagen and Astellas

Faculty Disclosure

Primary Author

Toni K. Choueiri, MD

Director, Lank Center for Genitourinary Oncology
Medical Director, International Strategic Initiatives
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts 

Toni K. Choueiri, MD, has disclosed that he has received paid and unpaid support either personal or institutional for research, advisory boards, consulting, and honoraria from Aravive, AstraZeneca, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Infinity, Ipsen, IQVA, Janssen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, and Tempest and has ownership interest in NuscanDx, Osel, Pionyr, and Tempest.

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Exelixis, Incyte, Janssen, Lilly, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seattle Genetics, and Urogen; has received funds for research support paid to his institution from Ada Cap (Advanced Accelerator Applications), Agensys, Astellas, AstraZeneca, Bayer, BioXcel, Bristol-Myers Squibb, Clovis Oncology, Eisai, Endocyte, Genentech, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi, and Seattle Genetics; and has ownership interest in Bellicum and Tyme.